There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

An indigenous low-cost point-of-care (PoC) testing approach has shown promise in making screening for Human Papillomavirus (HPV) more affordable and accessible, potentially improving the early detection of cervical cancer, according to a joint study led by researchers from AIIMS, ICMR, and the WHO's International Agency for Research on Cancer (IARC).

The study, published in the International Journal of Cancer, found that PoC tests have the potential to become scalable, low-cost screening tools in India and other low- and middle-income countries (LMICs).

The objective of the study was to evaluate indigenous HPV DNA testing platforms for use in primary cervical cancer screening.

Four Indigenous Tests Evaluated

While several Indian HPV tests have been developed, many had not yet been validated against the international standards laid down by the WHO.

The study evaluated four point-of-care tests developed by 3 Indian companies:

• Genes2Me – HPV-Q
• Mylabs India – PathoDetect HPV-7 and PathoDetect HPV-14
• Molbio Diagnostics – Truenat HR-HPV-Plus

Each test was developed by repurposing existing COVID-19 RT-PCR platforms. HPV-Q and PathoDetect HPV-14 can detect all 14 high-risk HPV types, while PathoDetect HPV-7 detects seven high-risk types: 16, 18, 31, 33, 45, 52, and 58.

How the Tests Performed

Also read: PM Modi Launches Nationwide Free HPV Vaccination Drive; A Landmark Step, Says WHO

To assess performance, researchers analyzed 1,159 cervical samples collected from studies conducted in Argentina and Costa Rica.

The results showed:

• Truenat HR-HPV-Plus: Sensitivity 80.4%, specificity 91.5% — met IARC validation criteria.
• PathoDetect HPV-7: Sensitivity 68.1%, specificity 89.0% — lower sensitivity.
• HPV-Q and PathoDetect HPV-14: Did not meet validation criteria.

Indigenous Platforms Can Be Game-Changers

"This study demonstrates that indigenous platforms can achieve clinical validation, quality standards, and accuracy comparable to global gold-standard tests. It will be a game-changer for cervical cancer prevention and early detection in India," said lead author Dr Neerja Bhatla, Professor Emeritus, NCI and former Head of the Department of Obstetrics & Gynecology at AIIMS New Delhi.

Dr Shalini Singh, Director of ICMR-NICPR, added that HPV DNA testing at age 35 and again at age 45 is central to WHO's cervical cancer elimination strategy, but high costs remain a major barrier in LMICs.

"Affordable indigenous solutions are essential to expand screening coverage and reduce disease burden," she said.

High Burden Of Cervical Cancer: Why HPV Testing Matters

Read More: HPV Vaccine Can Help Curb Rising Head And Neck Cancers, Says Top US Doctor

Cervical cancer continues to be a major public health challenge in India, with around 127,000 new cases and 80,000 deaths reported annually.

Globally, cervical cancer is the fourth most common cancer in women. According to WHO data for 2022, there were approximately 662,000 new cases and 348,000 deaths worldwide.

Regular screening of women over 30 years of age every 3-5 years can help detect precancerous and cancerous lesions early. However, screening coverage in India has remained low despite the inclusion of visual inspection with acetic acid (VIA) in the national screening program for breast, oral, and cervical cancers.

Persistent infection with carcinogenic HPV types is the necessary cause of cervical cancer. WHO recommends a transition to HPV testing as the preferred strategy for cervical cancer elimination.

Using validated HPV tests, only two rounds of screening — at ages 35 and 45 — may be sufficient to help achieve elimination targets. However, most existing HPV tests are expensive, require sophisticated laboratory infrastructure, and are not easily available at last-mile health facilities.

The researchers said that the point-of-care HPV testing approach, thus, could be a major breakthrough, enabling affordable diagnostics and even same-day treatment for women who test positive.

Potential for Nationwide Rollout

The researchers noted that while the recently introduced national HPV vaccination campaign will benefit younger generations, there remains an urgent need to expand HPV testing for women over 30 who are currently at risk of cervical cancer.

Dr Showket Hussain of the ICMR-National Institute of Cancer Prevention and Research (NICPR), Noida, said the validated platform has strong potential for integration into national screening programs because district-level healthcare personnel are already familiar with similar testing systems.

"Future advancements such as self-sampling and high-throughput adaptations could further enhance accessibility," he said.

The findings are expected to support India's cervical cancer elimination goals while offering a scalable model for other low-resource settings globally.

Cancer patients in India, already affected by shortages of critical chemotherapy drugs, are now set to face higher costs after the government approved a price hike.

Facing significant shortages are Cisplatin and Carboplatin — the two platinum-based drugs that form the backbone of treatment for common cancers such as oral cancer, breast cancer, ovarian cancer, cervical cancer, esophageal cancer, and testicular cancer.

Shortages Disrupt Cancer Treatment

The shortage of these essential chemotherapy medicines is disrupting care across hospitals and cancer centers, with several doctors pointing out that a substantial proportion of chemotherapy protocols for solid tumors rely on one of these platinum-based agents.

The drugs have been facing shortages as companies find it difficult to sustain production amid rising manufacturing costs linked to the ongoing conflict in the Middle East.

The two drugs, often prescribed in combination and with no alternatives, are derived from platinum, a precious metal whose cost has surged due to the Middle East conflict and the closure of the Strait of Hormuz.

Rising Production Costs Hit Manufacturers

Also read: India Revises Folic Acid Measurement Unit to Prevent Dosage Errors

"The production cost has increased because the API, or active pharmaceutical ingredient, which is imported from abroad, has become more expensive. As a result, manufacturing costs have gone up, but the MRP has not increased," Dr Shyam Agarwal, Senior Consultant, Medical Oncology at Sir Ganga Ram Hospital, told HealthandMe.

As companies have struggled to sustain production amid rising manufacturing costs, they approached the government seeking a revision of the price cap.

Drugmakers reportedly sought price revisions for 82 medicines, citing substantial increases in production costs due to the US-Iran conflict linked to the Hormuz crisis and other factors.

Government Approves Higher Prices

In response, the National Pharmaceutical Pricing Authority (NPPA), following permission from the Union government's Department of Pharmaceuticals (DoP), has increased maximum retail prices for four drugs, including the life-saving cancer medicines Cisplatin and Carboplatin, and two anti-tetanus injections.

While the move is aimed at restoring supplies, it has also raised concerns about affordability for patients already battling a costly disease.

The NPPA is the country's drug price regulator and functions under the DoP, Ministry of Chemicals and Fertilizers.

NPPA Asked to Review Cost Increases

Read More: India's Maternal Mortality Ratio Drops From 130 To 87 In Last 10 Years: Govt

The ministry directed the pricing authority to determine how much prices could be increased.

The formula suggested: "The Standing Committee recommended a 10 per cent increase per year from the last fixation with a ceiling of 50 per cent, which could also be a guide, but the primary principle should be cost increase," News18 reported.

The DoP has further advised the NPPA to examine increases in raw material costs for these drugs while determining any price revisions. It has also asked the regulator to assess similar requests from the pharmaceutical industry, where price hikes have been sought due to higher raw material costs.

India's Ministry of Health has notified an amendment to the Drugs Rules, 1945, replacing the unit of measurement for folic acid under Schedule V from "mg" (milligrams) to "mcg" (micrograms).

The amendment has been brought into effect through the Drugs (Fourth Amendment) Rules, 2026, notified vide Gazette Notification G.S.R. 444(E) dated June 1, 2026. The notification will come into force after six months, according to the Ministry.

The move aims to avoid unnecessary confusion, reduce the chances of misinterpretation, and prevent incorrect administration of dosages of vitamin B9 — essential for the production of healthy red blood cells, especially during pregnancy.

The change follows the publication of draft rules in January 2026 and consideration of objections and suggestions received from stakeholders.

What Does The New Notification Say?

Also read: India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

As per the notification, in Schedule V of the Drugs Rules, 1945, under paragraph 2 relating to standards for patent or proprietary medicines, the entry against "Folic acid" in the unit column has been amended. The earlier unit "mg" has now been substituted with "mcg".

The amendment will correct the unit of measurement, bringing it in line with internationally accepted dosing standards for folic acid, which is routinely prescribed and labelled in micrograms. This correction is also important because lower doses of folic acid are used prophylactically in situations such as pregnancy to prevent infant malformations. Higher doses, however, may be used to address specific conditions such as neural tube defects, Medical Dialogues reported.

The Ministry stated that the amendment has been made after consultation with the Drugs Technical Advisory Board (DTAB) and in exercise of the powers conferred under Sections 12 and 33 of the Drugs and Cosmetics Act, 1940.

According to the notification, the Drugs (Fourth Amendment) Rules, 2026, will come into force six months from the date of publication in the Official Gazette, giving manufacturers and other stakeholders sufficient time to make necessary compliance-related changes in product documentation, labelling, and regulatory records.

Why Is Folic Acid Important?

Read More: Introducing Eggs Before Age One May Lower Allergy Risk by 17%: Study

According to the American College of Obstetricians and Gynecologists (ACOG), folic acid is one of the most important nutrients in prenatal vitamins. This B vitamin helps create the baby's neural tube — the structure that eventually forms the brain and spinal cord.

Beyond pregnancy, people who do not consume enough folate- or folic acid-rich foods may develop folate deficiency. People with celiac disease and inflammatory bowel disease, which prevent the small intestine from absorbing nutrients properly, may also have low folate levels, as per the Mayo Clinic.

Folate is found mainly in

• dark green leafy vegetables,
• beans,
• peas,
• nuts.

Fruits rich in folate include

• oranges,
• bananas,
• melons,
• papayas.

The recommended daily amount of folate for adults is 400 micrograms (mcg). People who are planning a pregnancy or could become pregnant should get 400 to 800 mcg of folic acid daily.

Importantly, taking too much folic acid, especially over 1,000 mcg daily without a doctor's advice, can mask a vitamin B12 deficiency, potentially causing irreversible nerve damage and may lead to side effects such as bitter taste, nausea or sleep problems, with potential links to increased risks in pregnancy like autism or insulin resistance.